BRL 35135: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 122186 |
| CHEMBL ID | 49289 |
| SCHEMBL ID | 4611391 |
| MeSH ID | M0174460 |
| Synonym |
|---|
| brl35135a |
| methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate |
| brl 35135 |
| acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-, methyl ester |
| CHEMBL49289 |
| L003499 |
| 91097-81-3 |
| SCHEMBL4611391 |
| n-[2-(4-carbomethoxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-chlorophenyl) ethanamine |
| methyl 4-[2-[(3-chloro-beta-hydroxyphenethyl) amino]propyl]phenoxyacetate |
| ZFLBZHXQAMUEFS-UHFFFAOYSA-N |
| 4-[2-(2-(3-chlorophenyl)-2-hydroxyethylamino)propyl]phenoxya cetic acid methyl ester |
| DTXSID90919975 |
| methyl [4-(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}propyl)phenoxy]acetate |
| Excerpt | Reference |
|---|---|
| "BRL 35135 is a novel oral agent which, when dosed chronically to obese rodents with abnormal glucose tolerance, improves both insulin sensitivity and glucose tolerance. " | ( Cawthorne, MA; Ellis, RD; Mitchell, TH; Robb, G; Smith, SA, 1989) |
| Excerpt | Reference |
|---|---|
| "BRL 35135 treatment doubled BAT uncoupling protein mRNA levels (p < 0.05), and increased core temperature by 0.4 degree C (p < 0.05), but neither hypothalamic regional NPY levels nor hypothalamic NPY mRNA levels were affected by BRL 35135." | ( Bing, C; Buckingham, R; Frankish, H; Hopkins, D; Wang, Q; Williams, G, 1998) |
| "BRL 35135 treatment increased expression levels of beta3-AR mRNA in both genotypes." | ( Cawthorne, MA; Emilsson, V; Hamilton, S; Liu, YL; Summers, RJ, 1998) |
| "3. Treatment with BRL 35135 reduced weight gain by 19%, increased brown adipose tissue thermogenic activity 45-fold and reduced plasma insulin by 50%." | ( Hänninen, V; Huupponen, R; Jhanwar-Uniyal, M; Koulu, M; Pesonen, U; Rouru, J; Santti, E, 1994) |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID235309 | Ratio of the dose raising the rat heart rate to 500bpm, to ED50 for inhibition of GDP binding to beta-3 adrenergic receptor | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates. |
| AID41942 | Inhibition of beta-3 adrenergic receptor GDP binding in rat brown adipose tissue on oral administration relative to isoprenaline | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates. |
| AID41943 | Dose necessary to produce 50% of the isoprenaline effect to inhibit GDP binding to beta-3 adrenergic receptor in brown adipose tissue (BAT mitochondria) of rats after subcutaneous administration. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates. |
| AID235307 | Ratio of the dose (D500,peroral administration) elevating the rat heart rate to 500 bpm to the GDP ED50. | 1992 | Journal of medicinal chemistry, May-15, Volume: 35, Issue:10 | Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 32 (84.21) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 1 (2.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (7.89%) | 5.53% |
| Reviews | 1 (2.63%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 34 (89.47%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| Contrasts between the effects of zinc-α2-glycoprotein, a putative β3/2-adrenoceptor agonist and the β3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. The Journal of endocrinology, Volume: 216, Issue: 2 | 2013 |
| Effect of the beta-adrenoceptor agonist BRL-35135 on development of obesity in suckling Zucker (fa/fa) rats. The American journal of physiology, Volume: 268, Issue: 6 Pt 1 | 1995 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |